Logo

Sumitomo Dainippon's Latuda (lurasidone HCl) Receives NMPA's (CFDA) Approval for Schizophrenia

Share this

Sumitomo Dainippon's Latuda (lurasidone HCl) Receives NMPA's (CFDA) Approval for Schizophrenia

 Shots:
  • The approval is based on P-III clinical studies results assessing Latuda (n=245) vs Placebo (n=233) in 483 patients with schizophrenia
  • The study results: PANSS @6weeks (-19.3 vs -12.7); AEs (47.0% vs 51.1%); discontinued patients (5.7% vs 6.4%); improvement in CGI-S @6 weeks; well tolerated in patients
  • Lurasidone (40/80 mg/day; flexible dose) is an antipsychotic candidate with antagonist effects for D2-5-HT2A and 5-HT7 receptors- and has received approval from the US in 2010- Canada in 2012- Switzerland in 2012- EU and Australia IN 2014 with awaited Japan approval in H1’19 for Schizophrenia
  Ref: Sumitomo Dainippon | Image: Doug Lipp

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions